Search results for "SLIT-tablet"

showing 1 items of 1 documents

SQ HDM SLIT-tablet (ALK) in treatment of asthma – Post hoc results from a randomised trial

2014

SummaryIntroductionIn a double-blind, placebo-controlled trial (EudraCT identifier: 2006-001795-20), the standardised quality (SQ) house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet (ALK, Denmark) was investigated.MethodThe trial included 604 subjects, ≥14 years, with mild-moderate HDM allergic asthma. Subjects were randomised 1:1:1:1 to 1, 3 or 6 SQ-HDM or placebo once daily. The primary endpoint was reduction in inhaled corticosteroid (ICS) after one year. ICS reduction, asthma quality of life questionnaire (AQLQ) and asthma control questionnaire (ACQ) score was analysed post hoc in a subgroup with daily ICS use of 400–800 μg and ACQ score of 1–1.5, corresponding to partly contr…

AdultPulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtymedicine.drug_classPopulationPlaceboHouse dust miteDouble-Blind MethodQuality of lifeSurveys and QuestionnairesmedicineClinical endpointAnimalsHumansSLIT-tabletBudesonideeducationGlucocorticoidsICS reductionAsthmaHouse dust miteSublingual Immunotherapyeducation.field_of_studybiologybusiness.industryPyroglyphidaemedicine.diseasebiology.organism_classificationAsthma; Asthma quality of life; House dust mite; ICS reduction; SLIT-tabletAsthmaTreatment OutcomeAsthma Control QuestionnaireQuality of LifeCorticosteroidAsthma quality of lifebusinessTabletsRespiratory Medicine
researchProduct